Curetoday.comCancer Network

Curetoday.comCancer Network
Share

Curetoday.comCancer Network

 •  November 9, 2017

Another agent – Cinvanti (aprepitant) injectable emulsion – was approved by the Food and Drug Administration (FDA) to treat chemotherapy-induced nausea/vomiting (CINV). Another agent – Cinvanti (aprepitant) injectable emulsion – was approved by the Food and Drug Administration (FDA) to treat chemotherapy-induced nausea/vomiting (CINV). The drug...

Curetoday.comCancer Network

 •  June 6, 2017

Many patients with relapsed or refractory multiple myeloma saw clinical remission with CAR T-cell therapy. When treated with chimeric antigen receptor (CAR) T cells targeting B-cell maturation protein (BMCA) in an early Chinese study, 94 percent (33 of 35 patients) with relapsed or refractory multiple myeloma saw clinical remission. In findings...

Curetoday.comCancer Network

 •  May 26, 2017

Axicabtagene ciloleucel (KTE-C19; axi-cel) was granted a priority review by the Food and Drug Administration (FDA) for the treatment of transplant-ineligible patients with relapsed or refractory non-Hodgkin lymphoma (NHL). Axicabtagene ciloleucel (KTE-C19; axi-cel) was granted a priority review by the Food and Drug Administration (FDA) for the...

Curetoday.comCancer Network

 •  May 4, 2017

The time sitting in the infusion chair before receiving chemotherapy can be a challenge, but a team of nurses are working to improve the patient experience. Along with the many challenges that come with cancer treatment, having to wait a long time in the infusion chair before receiving chemotherapy or other anticancer IV medications should not be...

Curetoday.comCancer Network

 •  June 5, 2016

Women who received intraperitoneal chemotherapy after surgery for ovarian cancer had a reduced amount of disease progression when compared with those who received chemotherapy via IV. Intraperitoneal chemotherapy (IP), which delivers the medicine directly into the abdominal cavity, is beneficial and tolerable, and physicians should present it as an...